Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection
2010
Advancements in Hepatitis C Treatment
Sample size: 122
Editorial
Evidence: moderate
Author Information
Author(s): Tatehiro Kagawa, Emmet B. Keeffe, Ming-Lung Yu
Conclusion
The treatment of chronic hepatitis C has significantly improved over the past 20 years, with sustained virologic response rates increasing from less than 10% to close to 75% with new therapies.
Supporting Evidence
- The sustained virologic response (SVR) rate increased from 8%-9% with interferon monotherapy to 30% with ribavirin, and then to 40%-50% with peginterferon plus ribavirin.
- Recent literature shows that achieving an SVR leads to slowed disease progression and improved health outcomes.
- Adherence to peginterferon and ribavirin was the only predictor of SVR in a study of 122 patients.
Takeaway
Doctors have found better ways to treat hepatitis C, helping more people get better over the years.
Participant Demographics
Patients with chronic hepatitis C, including special populations like those undergoing chemotherapy and hemodialysis.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website